CIK 0001691082 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | |
|---|---|
| Net income (USD) | -25.2 M |
| Diluted EPS (USD/shares) | -3.13 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-13 | 4 | 4 | 2026-10-09 |
| 2026-10-13 | 4 | 4 | 2026-10-09 |
| 2026-10-13 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-10-05 | EFFECT | EFFECT items ,, | |
| 2026-10-01 | POS AM | POS AM | |
| 2026-10-01 | S-3ASR | S-3ASR | |
| 2026-09-24 | 3 | 3 | 2026-09-14 |
| 2026-09-15 | 424B3 | 424B3 | |
| 2026-09-15 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-09-15 |
| 2026-09-14 | 3 | 3 | 2026-09-02 |
| 2026-09-03 | 424B3 | 424B3 | |
| 2026-09-03 | 8-K | 8-K items 5.02,7.01,9.01 | 2026-09-03 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-11 | 424B3 | 424B3 | |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-11 | 8-K | 8-K items 2.02,9.01 | 2026-08-11 |
| 2026-08-03 | 4 | 4 | 2026-07-30 |
| 2026-07-29 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-29 | 424B3 | 424B3 | |
| 2026-07-29 | 8-K | 8-K items 1.01,3.02,7.01,9.01 | 2026-07-28 |
| 2026-07-22 | 424B3 | 424B3 | |
| 2026-07-22 | 8-K | 8-K items 8.01,9.01 | 2026-07-22 |
| 2026-07-16 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-06-10 | 424B3 | 424B3 | |
| 2026-06-10 | 8-K | 8-K items 5.02,9.01 | 2026-06-08 |
Forms on file (last 1,000): 4 29, 3 20, 8-K 16, 424B3 9, SCHEDULE 13G 9, D 9, SCHEDULE 13G/A 8, CORRESP 5. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=LBRX (0.002 USD), /gw/filings/filings?ticker=LBRX&form=8-K, /gw/filings/facts?ticker=LBRX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange